spacer
home > events calendar > more about event
PHARMACEUTICAL INDUSTRY EVENTS CALENDAR

Adaptive Designs in Clinical Trials

9-10 April 2018
Copthorne Tara Hotel, Scarsdale Place, Kensington, London, UK

Now running for 10 years, SMiís annual conference on  Adaptive Designs in Clinical Trials will return to London on 9thand 10th April 2018.

This yearís agenda has been curated to provide you with the latest innovations, regulatory updates, and strategies on how industry and clinical experts are currently using adaptive designs in their clinical trials for successful drug, medical device and therapy development.

Giving you a fresh take on this vital area of biopharma, the event will ride the wave of technology within the pharmaceutical industry, as we consider how the increasing use of smartphone apps and digital devices is changing the way trials run. Simultaneously, the event will also explore how adaptive designs are being used for the production of personalised medicines and personalised therapies.

Featured Speakers include:

  • James Matcham, Head of Biometrics, Early Clinical Development, AstraZeneca
  • Alex Sverdlov, Director, Statistical Scientist, Novartis
  • Frank Fleisher, Principal Methodology Statistician, Boehringer-Ingelheim
  • Christine Fletcher, Executive Director Biostatistics, Amgen
  • Chris Harbron, Principal Statistical Scientist, Roche
  • Olivier Collignon, Biostatistician, European Medicines Agency
  • Beatrice Panico, Medical Advisor, MHRA
  • Corine Baayen, Senior Biostatistician, H.Lundbeck

Key Highlights

  • Explore the current industry outlook and evaluate the promises and challenges of digital technology use
  • Hear exciting case studies on enrichment designs and group sequential trials
  • Discover how big pharma companies are using Platform Trials and self-adapting priors to advance their adaptive clinical trials
  • Examine the use of adaptive clinical trials are used to produce targeted therapies
  • Learn from the latest regulatory perspectives from MHRA and EMA, including planning and assessing umbrella and basket trials

Early Bird: Book by Dec 15 to save £400. Book by Jan 31 to save £200. Book by 28 Feb to save £100.

Contact details of organiser

Alan Caddick | Senior Marketing Executive | SMi Group Ltd 
T: +44 (0) 207 827 6038 | acaddick@smi-online.co.uk

 
Print this page
Send to a friend
   
spacer
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

White Papers

Utilising Big Data to Produce Faster and Cheaper Clinical Research

Medical Research Network (MRN) Limited

Recruitment and retention of patients remains the major challenge to ensuring trials run as fast as possible and give them the statistical power they are designed to produce. This is not just about getting better any more - but about stopping the deterioration of these metrics in modern clinical trials.
More info >>


News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement